Zhai Kui, Jiang Ni, Wen Ji-Fan, Zhang Xiao, Liu Tao, Long Kai-Jun, Ke Xi-Xian, Xu Gang, Chen Cheng
Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
J Thorac Dis. 2023 May 30;15(5):2644-2658. doi: 10.21037/jtd-23-395. Epub 2023 May 22.
It has been reported that twinfilin actin binding protein 1 (TWF1) is associated with the progression of breast and pancreatic cancers. However, the roles and mechanisms of TWF1 in lung adenocarcinoma (LUAD) have not been reported.
The expression levels of TWF1 in LUAD and normal tissues were analyzed using The Cancer Genome Atlas (TCGA) database, and validation was carried out with 12 clinical samples. The relationship between TWF1 expression and LUAD patients' clinical indices and immunity was investigated. Cell Counting Kit-8 (CCK-8) and migration and invasion assays were employed to explore the effects of downregulated TWF1 on LUAD cell proliferation and metastasis.
TWF1 was upregulated in LUAD tissues, and upregulated TWF1 was correlated with the tumor (T) stage, node (N) stage, clinical classification, overall survival (OS), and progression-free interval (PFI) of LUAD patients. Moreover, the Cox regression analysis showed that TWF1 overexpression was an independent risk factor for the poor prognosis of LUAD patients. TWF1 expression was associated with tumor immune infiltration (such as dendritic cells resting, eosinophils, macrophages M0, and others), drug sensitivity (such as A-770041, Bleomycin, and BEZ235), tumor mutation burden (TMB), and sensitivity to immunotherapy. In the cell model, TWF1 expression interference significantly prohibited LUAD cell proliferation, migration, and invasion, which might be relevant to aberrant MMP1 protein downregulation.
TWF1 overexpression was correlated with poor prognoses and immune status of LUAD patients. Inhibited TWF1 expression delayed the growth and migration of cancer cells by downregulating MMP protein, implying that TWF1 is a promising biomarker for the prognoses of LUAD patients.
据报道,双肌动蛋白结合蛋白1(TWF1)与乳腺癌和胰腺癌的进展有关。然而,TWF1在肺腺癌(LUAD)中的作用和机制尚未见报道。
使用癌症基因组图谱(TCGA)数据库分析TWF1在LUAD组织和正常组织中的表达水平,并对12个临床样本进行验证。研究TWF1表达与LUAD患者临床指标及免疫之间的关系。采用细胞计数试剂盒-8(CCK-8)以及迁移和侵袭实验,探讨下调TWF1对LUAD细胞增殖和转移的影响。
TWF1在LUAD组织中上调,TWF1上调与LUAD患者的肿瘤(T)分期、淋巴结(N)分期、临床分类、总生存期(OS)和无进展生存期(PFI)相关。此外,Cox回归分析表明,TWF1过表达是LUAD患者预后不良的独立危险因素。TWF1表达与肿瘤免疫浸润(如静息树突状细胞、嗜酸性粒细胞、M0巨噬细胞等)、药物敏感性(如A-770041、博来霉素和BEZ235)、肿瘤突变负荷(TMB)以及免疫治疗敏感性有关。在细胞模型中,TWF1表达干扰显著抑制LUAD细胞的增殖、迁移和侵袭,这可能与MMP1蛋白异常下调有关。
TWF1过表达与LUAD患者的不良预后和免疫状态相关。抑制TWF1表达通过下调MMP蛋白延迟癌细胞的生长和迁移,这意味着TWF1是LUAD患者预后的一个有前景的生物标志物。